2,1,3-苯并噻二唑-4-甲醛 | 5170-68-3

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻二唑类
• 中文名称: 2,1,3-苯并噻二唑-4-甲醛
• 中文别名: 2,1,3-苯并噻唑-4-羰醛；2,4,6-三氯联苯
• 英文名称: 2,1,3-benzothiadiazole-4-carboxaldehyde
• 英文别名: 4-formyl-2,1,3-benzothiadiazole；2,1,3-benzothiadiazol-4-carboxaldehyde；benzo[c][1,2,5]thiadiazole-4-carbaldehyde；2,1,3-benzothiadiazole-4-carbaldehyde
• CAS: 5170-68-3
• 化学式: C₇H₄N₂OS
• mdl: MFCD02681902
• 分子量: 164.188
• InChiKey: ANVJARPTPIVPRC-UHFFFAOYSA-N

物化性质

• 熔点：
  99 °C
• 沸点：
  291.9±13.0℃ (760 Torr)
• 密度：
  1.477±0.06 g/cm3 (20 ºC 760 Torr)
• 闪点：
  130.3±19.8℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	2 1 3-Benzothiadiazole-4-carbaldehyde 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	5170-68-3

Section 1 - Chemical Product MSDS Name:2 1 3-Benzothiadiazole-4-carbaldehyde 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5170-68-3	2,1,3-Benzothiadiazole-4-carbaldehyde	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Air sensitive.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation. Place under an inert atmosphere.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Avoid contact with skin and eyes. Keep container tightly closed. Avoid ingestion and inhalation. Handle under an inert atmosphere. Store protected from air.
Storage:
Store in a cool, dry place. Store in a tightly closed container. Do not expose to air. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5170-68-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: characteristic odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 101 - 102 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H4N2OS
Molecular Weight: 164.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Air sensitive.
Conditions to Avoid:
Dust generation, exposure to air.
Incompatibilities with Other Materials:
Acids, bases, oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5170-68-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,1,3-Benzothiadiazole-4-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 5170-68-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5170-68-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5170-68-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,1,3-苯并噻二唑-4-甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以67%的产率得到苯并[C][1,2,5]噻二唑-4-基甲醇
  参考文献：
  名称：

  An Original Way for Synthesis of New Nitrobenzothiadiazole Derivatives

  摘要：

  The C-alkylation reaction of 4-chloromethyl-7-nitro-2,1,3-benzothiadiazole with 2-nitropropane anion which is shown to proceed by an S(RN)1 mechanism is an original way for the synthesis of new 2,1,3-benzothiadiazoles.

  DOI：

  10.3987/com-97-7744
• 作为产物：
  描述：

  2,1,3-苯并噻二唑 在 哌啶 、 盐酸 、 聚合甲醛 、 三氯化铝 作用下， 生成 2,1,3-苯并噻二唑-4-甲醛
  参考文献：
  名称：

  Studies in the field of 2, 1, 3-Thiadiazole and 2,1, 3-Selenadiazole

  摘要：

  DOI：

  10.1007/bf00474878

文献信息

• 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：US20190194189A1

  公开（公告）日：2019-06-27

  The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

  本发明提供了式(I)的1H-吡唑并[4,3-b]吡啶类化合物作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。
• Indol-3-yl derivatives
  申请人：——

  公开号：US20040138284A1

  公开（公告）日：2004-07-15

  Indol-3-yl derivatives of the general formula I 1 in which A, B, X, R 1 , R 2 , R 3 , R 4 , R 5 , n and m are as defined in Patent Claim 1, and their physiologically acceptable salts or solvates are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammations, tumours, osteoporosis, rheumatic arthritis, macular degenerative disease, diabetic retinopathy, infections and restenosis after angioplasty or in pathological processes maintained or propagated by angiogenesis.

  通用公式I的Indol-3-基衍生物 其中A、B、X、R1、R2、R3、R4、R5、n和m的定义如专利权要求书中所定义 1， 及其生理上可接受的盐或溶剂是整合素抑制剂，可用于对抗血栓形成、心肌梗死、冠心病、动脉硬化、炎症、肿瘤、骨质疏松症、风湿性关节炎、黄斑变性疾病、糖尿病视网膜病变、感染以及血管成形术后的再狭窄或由血管生成维持或传播的病理过程。
• Biomimetic hydrogen-bonding cascade for chemical activation: telling a nucleophile from a base
  作者：Hyunchang Park、Dongwhan Lee

  DOI：10.1039/d0sc05067a

  日期：——

  Hydrogen bonding-assisted polarization is an effective strategy to promote bond-making and bond-breaking chemical reactions. Taking inspiration from the catalytic triad of serine protease active sites, we have devised a conformationally well-defined benzimidazole platform that can be systematically functionalized to install multiple hydrogen bonding donor (HBD) and acceptor (HBA) pairs in a serial

  氢键辅助极化是促进成键和断键化学反应的有效策略。从丝氨酸蛋白酶活性位点的催化三联体中汲取灵感，我们设计了一个构象明确的苯并咪唑平台，该平台可以系统地功能化，以串行方式安装多个氢键供体 (HBD) 和受体 (HBA) 对。我们发现，越来越多的相互依赖和相互增强的 HBD-HBA 接触促进了荧光猝灭醛基与氰化物离子的成键反应，同时抑制了不希望的 Brønsted 酸碱反应。最先进的系统，通过迭代的规则发现研究发展起来，对 CN 做出快速和选择性的反应-在λ max = 450 nm 处产生大的（> 180 倍）荧光强度增强。
• [EN] THERAPEUTIC AGENTS I<br/>[FR] AGENTS THERAPEUTIQUES I
  申请人：ASTRAZENECA AB

  公开号：WO2005066132A1

  公开（公告）日：2005-07-21

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的化学式(I)，制备这种化合物的方法，它们在治疗肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫以及相关疾病，以及神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病中的应用，以及含有它们的药物组合物。
• Synthesis and biological evaluation of aminothiazoles against Histoplasma capsulatum and Cryptococcus neoformans
  作者：Keisuke Ishita、Stavros Stefanopoulos、Ahmed Khalil、Xiaolin Cheng、Werner Tjarks、Chad A. Rappleye

  DOI：10.1016/j.bmc.2018.01.024

  日期：2018.5

  group, the thiazole core, and the methylene linker between these two structural elements. In general, compounds with lipophilic [5+6] bicyclic ring systems, such as the 7-benzothiophenyl- and 4-indanyl groups, at the 5-position were 2–3 times more active against both fungal species as compared to 41F5. Also, introduction of a carbonyl group at the methylene linker of 41F5 resulted in a 2–3-fold increase

  描述了四十种新型 2-氨基唑类似物库的设计和合成，以及它们作为抗荚膜组织胞浆菌和新型隐球菌的抗真菌化合物的评估。这些结构源自N -[5-(1-萘基甲基)-2-噻唑基]环己烷甲酰胺 (41F5)，这是一种先前通过表型筛选鉴定的抑真菌剂（ Antimicrob Agents Chemother. 2013；57:4349）。提高 41F5 效力和水溶性的修饰主要集中在 5-萘基、噻唑核心以及这两个结构元件之间的亚甲基连接基。一般来说，5 位具有亲脂性 [5+6] 双环系统（例如 7-苯并噻吩基和 4-茚满基）的化合物对两种真菌的活性比 41F5 高 2-3 倍。此外，在 41F5 的亚甲基连接基上引入羰基导致效力增加 2-3 倍。这些高活性化合物还对鼠 P388D1 巨噬细胞表现出较低的毒性，导致选择性指数范围为 63 至 >200。对氟康唑敏感的新型隐球菌菌株具有高度活性的化合物对这种真菌的氟康唑抗性变种具有几乎相同的活性，表明